Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

61. Web-Based Communication Strategies Designed to Improve Intention to Minimize Risk for Colorectal Cancer: Randomized Controlled Trial

Web-Based Communication Strategies Designed to Improve Intention to Minimize Risk for Colorectal Cancer: Randomized Controlled Trial Web-Based Communication Strategies Designed to Improve Intention to Minimize Risk for... - Europe PMC Article - Europe PMC 1 Europe PMC requires Javascript to function effectively. Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page (...) . or https://orcid.org https://plus.europepmc.org/emss/sub.cgi?page=logoff Search worldwide, life-sciences literature Search E.g. "breast cancer" HER2 Smith J People seek information on the Web for managing their colorectal cancer (CRC) risk but retrieve much personally irrelevant material. Targeting information pertinent to this cohort via a frequently asked question (FAQ) format could improve outcomes.We identified and prioritized colorectal cancer information for men and women aged 35 to 74 years

JMIR cancer2018 Full Text: Link to full Text with Trip Pro

62. Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectal cancer cells

Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectal cancer cells 29743857 2018 11 14 1611-2156 17 2018 EXCLI journal EXCLI J Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectal cancer cells. 186-199 10.17179/excli2018-1011 Colorectal cancer (CRC) is the third most leading cause of morbidity and mortality throughout the world. 5-fluorouracil (5-FU), which is often administrated to disrupt (...) 12084459 Int J Oncol. 2011 Sep;39(3):673-82 21674128 PLoS One. 2013 Nov 21;8(11):e81264 24278407 World J Gastroenterol. 2007 Mar 14;13(10):1534-40 17461445 Nat Rev Mol Cell Biol. 2004 Oct;5(10 ):792-804 15459660 Molecules. 2008 Aug 05;13(8):1551-69 18794772 Eur J Cancer. 1997 Oct;33(11):1896-9 9470854 Colorectal Dis. 2012 Nov;14(11):1307-12 23046351 Diabetes. 2006 Jul;55(7):2115-25 16804083 Anticancer Res. 2009 Jan;29(1):435-41 19331183 DNA Cell Biol. 2014 Feb;33(2):64-72 24283362 Br J Surg. 2013 Oct

EXCLI journal2018 Full Text: Link to full Text with Trip Pro

63. Lonsurf for Metastatic Colorectal Cancer – Details

Lonsurf for Metastatic Colorectal Cancer – Details Lonsurf for Metastatic Colorectal Cancer – Details | CADTH.ca Français Français Find the information you need Lonsurf for Metastatic Colorectal Cancer – Details Lonsurf for Metastatic Colorectal Cancer – Details Project Number pCODR 10122 Brand Name Lonsurf Generic Name Trifluridine and Tipiracil Tumour Type Gastointestinal Indication Metastatic Colorectal Cancer Funding Request For the treatment of adult patients with metastatic colorectal (...) cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents Review Status Pending Pre Noc Submission Yes NOC Date Manufacturer Taiho Pharma Canada, Inc. Submitter Taiho Pharma Canada, Inc. Submission Date (Target Date) November 3, 2017 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline (target date based on target

CADTH - Pan Canadian Oncology Drug Review2018

64. Microsatellite instability in colorectal cancer

Microsatellite instability in colorectal cancer 29743854 2018 11 14 1611-2156 17 2018 EXCLI journal EXCLI J Microsatellite instability in colorectal cancer. 159-168 10.17179/excli2017-948 Colorectal cancer (CRC) is a heterogeneous disease that is caused by the interaction of genetic and environmental factors. Although it is one of the most common cancers worldwide, CRC would be one of the most curable cancers if it is detected in the early stages. Molecular changes that occur in colorectal (...) molecular alteration and hyper-mutable phenotype, which is the result of a defective DNA mismatch repair (MMR) system, and can be defined as the presence of alternate sized repetitive DNA sequences which are not present in the corresponding germ line DNA. The presence of MSI is found in sporadic colon, gastric, sporadic endometrial and the majority of other cancers. Approximately, 15-20 % of colorectal cancers display MSI. Determination of MSI status in CRC has prognostic and therapeutic implications

EXCLI journal2018 Full Text: Link to full Text with Trip Pro

65. Erbitux for Left Sided Metastatic Colorectal Cancer – Details

Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details Project Number pCODR 10128 Brand Name Erbitux Generic Name Cetuximab Strength 2 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic Colorectal Cancer Funding Request For the first-line treatment (...) of RAS wild-type metastatic colorectalcarcinoma (mCRC) patients with left sided primary tumours Review Status Pending Pre Noc Submission No NOC Date September 9, 2005 Manufacturer Eli Lilly Canada Inc. Submitter Eli Lilly Canada Inc. Submission Date (Target Date) February 15, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date) ‡ March 2, 2018 Clarification The Submitter notified pCODR that they will be unable to submit

CADTH - Pan Canadian Oncology Drug Review2018

66. Vectibix for Left Sided Metastatic Colorectal Cancer — Details

Vectibix for Left Sided Metastatic Colorectal Cancer — Details Vectibix for Left Sided Metastatic Colorectal Cancer — Details | CADTH.ca Find the information you need Vectibix for Left Sided Metastatic Colorectal Cancer — Details Vectibix for Left Sided Metastatic Colorectal Cancer — Details Project Number pCODR 10118 Brand Name Vectibix Generic Name Panitumumab Tumour Type Gastrointestinal Indication Left Sided Metastatic Colorectal Cancer Funding Request For the treatment of patients (...) with left sided wild-type RAS metastatic colorectal cancer (mCRC) in the first line treatment setting with combination chemotherapy. Review Status Pending Pre Noc Submission No NOC Date Manufacturer Amgen Canada Inc. Submitter Amgen Canada Inc. Submission Date September 8, 2017 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date) ‡ Check-point meeting (target date) pERC Meeting (target date) Initial Recommendation Issued (target

CADTH - Pan Canadian Oncology Drug Review2018

67. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case | Esmo Open We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn (...) -amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case Article Text Original research Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case Erika Martinelli , Teresa Troiani , Vincenzo Sforza , Giulia Martini , Claudia Cardone , Pietro Paolo Vitiello , Davide Ciardiello , Anna Maria Rachiglio , Nicola Normanno , , Andrea Sartore-Bianchi , , Silvia Marsoni , Alberto

ESMO open2018 Full Text: Link to full Text with Trip Pro

68. The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement

The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement PREDICTIVE EFFECT OF PRIMARY TUMOUR LOCATION IN THE TREATMENT OF mCRC, Abrahao et al. 390 Current Oncology, Vol. 24, No. 6, December 2017 © 2017 Multimed Inc. PRACTICE GUIDELINE The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement A.B.K. Abrahao md , ‡a S. Karim md , †a B. Colwell md , § S (...) . Berry md mhs c, ‡ and J. Biagi md * ABSTRACT In recently published data, the predictive value of primary tumour location for the treatment of metastatic colorectal cancer with available biologic therapies has been explored. Recognizing the potential effect of those data on clini- cal practice, we convened a meeting of Canadian experts who treat metastatic colorectal cancer to develop a set of national, evidence-based treatment guidelines based on primary tumour location. This report summarizes

CMA Infobase (Canada)2018

69. Results from clinical effectiveness evaluations of screening for colorectal cancer: rapid review

Results from clinical effectiveness evaluations of screening for colorectal cancer: rapid review Results from clinical effectiveness evaluations of screening for colorectal cancer: rapid review - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • • Results from clinical effectiveness evaluations of screening for colorectal cancer: rapid review Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health (...) Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close Key message Background Most cases of colorectal cancer develop from benign precursors, so-called adenomas in the colon. Thus, methods for detecting colorectal cancers and its precursors are of major interest. One relevant approach is to conduct mass investigations of the population, or parts of it – “screening”. Commission As of now, two methods for colorectal cancer screening have

The Norwegian Knowledge Centre for the Health Services2018

70. Expected impact of introducing screening for colorectal cancer in Norway

Expected impact of introducing screening for colorectal cancer in Norway Expected impact of introducing screening for colorectal cancer in Norway - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • • Expected impact of introducing screening for colorectal cancer in Norway Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality

The Norwegian Knowledge Centre for the Health Services2018

71. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS | Annals of Oncology | Oxford Academic We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any (...) time. Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation January 2018 Article Navigation Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS T Yoshino Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East

European Society for Medical Oncology2018

72. Colorectal cancer

Colorectal cancer Colorectal cancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Colorectal cancer Last reviewed: August 2018 Last updated: January 2018 Summary Third most common cancer in the Western world. Rare below 40 years of age. Symptoms are not specific and occur frequently in benign colorectal conditions. Surgical resection is the main curative treatment. Combined modality treatment (chemotherapy (...) , radiotherapy, resection of metastases) has increased survival in selected cases. Definition The majority of colorectal cancers are adenocarcinomas derived from epithelial cells. About 71% of new colorectal cancers arise in the colon and 29% in the rectum. Toms JR, ed. CancerStats monograph 2004. London: Cancer Research; 2004. Less common types of malignant colorectal tumours are carcinoid tumours, GI stromal cell tumours, and lymphomas. Increasing age is the greatest risk factor for sporadic colorectal

BMJ Best Practice2018

73. An E-Learning Module to Improve Nongenetic Health Professionals’ Assessment of Colorectal Cancer Genetic Risk: Feasibility Study

An E-Learning Module to Improve Nongenetic Health Professionals’ Assessment of Colorectal Cancer Genetic Risk: Feasibility Study Multimedia appendix 1: Screenshots of a comic with questions

JMIR medical education2017 Full Text: Link to full Text with Trip Pro

74. Erbitux for Left Sided Metastatic Colorectal Cancer – Details

Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Erbitux for Left Sided Metastatic Colorectal Cancer – Details Erbitux for Left Sided Metastatic Colorectal Cancer – Details Project Number pCODR 10128 Brand Name Erbitux Generic Name Cetuximab Strength 2 mg/mL Tumour Type Gastrointestinal Indication Left Sided Metastatic Colorectal Cancer Funding Request For the first-line treatment (...) of RAS wild-type metastatic colorectalcarcinoma (mCRC) patients with left sided primary tumours Review Status Pending Pre Noc Submission No NOC Date September 9, 2005 Manufacturer Eli Lilly Canada Inc. Submitter Eli Lilly Canada Inc. Submission Date (Target Date) January 18, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline (target date based on target submission date) ‡ February 1, 2018 Check-point meeting (target date) pERC Meeting (target date) Initial

CADTH - Pan Canadian Oncology Drug Review2017

75. Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection

Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection 28895143 2017 09 19 2017 09 19 1365-2168 104 11 2017 Oct The British journal of surgery Br J Surg Randomized clinical trial of laparoscopic ultrasonography before laparoscopic colorectal cancer resection. 1462-1469 10.1002/bjs.10636 Intraoperative ultrasonography during open surgery for colorectal cancer may be useful for the detection of unrecognized liver metastases. Laparoscopic (...) ultrasonography (LUS) for the detection of unrecognized liver metastasis has not been studied in a randomized trial. This RCT tested the hypothesis that LUS would change the TNM stage and treatment strategy. Patients with colorectal cancer and no known metastases were randomized (1 : 1) to laparoscopic examination (control or laparoscopy plus LUS) in three Danish centres. Neither participants nor staff were blinded to the group assignment. Three hundred patients were randomized, 150 in each group. After

EvidenceUpdates2017

76. Is whole-colon investigation by colonoscopy, computerised tomography colonography or barium enema necessary for all patients with colorectal cancer symptoms, and for which patients would flexible sigmoidoscopy suffice? A retrospective cohort study

Is whole-colon investigation by colonoscopy, computerised tomography colonography or barium enema necessary for all patients with colorectal cancer symptoms, and for which patients would flexible sigmoidoscopy suffice? A retrospective cohort study Is whole-colon investigation by colonoscopy, computerised tomography colonography or barium enema necessary for all patients with colorectal cancer symptoms, and for which patients would flexible sigmoidoscopy suffice? A retrospective cohort study (...) Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} In patients referred to hospital with suspected colorectal cancer, symptom profiles are associated with cancer site and can

NIHR HTA programme2017

77. Colorectal Cancer Awareness: The Gastroenterology Resolution for the Future

Colorectal Cancer Awareness: The Gastroenterology Resolution for the Future E-Mail karger@karger.com Editorial GE Port J Gastroenterol 2018;25:55–56 DOI: 10.1159/000481861 Colorectal Cancer Awareness: The Gastroenterology Resolution for the Future Alexandre Oliveira Ferreira Gastroenterology Department, Hospital Beatriz Ângelo, Loures, Portugal and raise public awareness to promote screening, as it is in their best interest to increase cost-effective preventive measures. Unfortunately (...) Hospitalar de Setúbal in Portu- gal, try to fill in this gap and report their valuable experi- ence and the data gathered during a local awareness cam- paign designed and conducted by gastroenterologists and associated health professionals. Their aim was mainly to raise awareness by direct interaction with the public but Keywords Screening · Colorectal cancer · Adenoma Sensibilização para o Cancro Colo-Retal: O Desígnio da Gastrenterologia Nacional para o Futuro Palavras Chave Rastreio · Cancro colo

GE Portuguese journal of gastroenterology2017 Full Text: Link to full Text with Trip Pro

78. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial

Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial 1 Van Cutsem E, et al. ESMO Open 2017;2:e000261. doi:10.1136/esmoopen-2017-000261 Open Access Abstr Act Background In the pivotal phase III, randomised, double- blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). There was no formal (...) at discontinuation. Conclusions Analysis of ECOG PS and AEs thought to affect QoL in the RECOURSE patient population suggests that trifluridine/tipiracil treatment does not result in a deterioration of patient QoL versus placebo. Int Rodu Ct Ion Globally, colorectal cancer (CRC) is the third most commonly diagnosed cancer (~10% of new cases) and is responsible for 8% of cancer-related deaths. 1 It is now well known that quality of life (QoL) is an important issue for individuals with cancer, with QoL affected by

ESMO open2017 Full Text: Link to full Text with Trip Pro

79. QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer

QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer | Esmo Open We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer Article Text Original research QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal

ESMO open2017 Full Text: Link to full Text with Trip Pro

80. Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study.

Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study. Background: The fecal immunochemical test (FIT) for detecting hemoglobin is used widely for noninvasive colorectal cancer (CRC) screening, but its sensitivity leaves room for improvement. Objective: To identify novel protein biomarkers in stool that outperform or complement hemoglobin in detecting CRC and advanced adenomas. Design: Case-control study. Setting: Colonoscopy-controlled referral (...) population from several centers. Participants: 315 stool samples from one series of 12 patients with CRC and 10 persons without colorectal neoplasia (control samples) and a second series of 81 patients with CRC, 40 with advanced adenomas, and 43 with nonadvanced adenomas, as well as 129 persons without colorectal neoplasia (control samples); 72 FIT samples from a third independent series of 14 patients with CRC, 16 with advanced adenomas, and 18 with nonadvanced adenomas, as well as 24 persons without

Annals of Internal Medicine2017